Clinical Trials Browser

Phase 3 × ruxolitinib × Clear all

NCT04116502 2026-04-28

MITHRIDATE

Phase 3 Recruiting

Polycythemia Vera

NCT04562389 2026-04-09

SENTRY

Phase 3 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04472598 2026-03-23

TRANSFORM-1

Phase 3 Completed

252 enrolled 17 charts

Neoplasms, Primary Myelofibrosis

NCT04468984 2026-01-09

TRANSFORM-2

Phase 3 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Phase 3 Terminated

252 enrolled 18 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT04934670 2024-08-27

2002

Phase 3 Terminated

12 enrolled 12 charts

Pathologic Complete Response, Lymphoma, Follicular

NCT05663827 2024-03-05

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Phase 3 Completed

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02038036 2021-07-20

RESPONSE-2

Phase 3 Completed

149 enrolled 19 charts

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02292446 2019-07-18

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Phase 3 Completed

161 enrolled 14 charts

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02117479 2019-03-26

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Phase 3 Terminated

321 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01243944 2019-03-06

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Phase 3 Completed

222 enrolled 21 charts

Polycythemia Vera

NCT00952289 2018-03-12

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Phase 3 Completed

309 enrolled 18 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT02119663 2018-02-13

A Study of Ruxolitinib in Pancreatic Cancer Patients

Phase 3 Terminated

86 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01632904 2017-11-14

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Phase 3 Completed

110 enrolled 11 charts

Polycythemia Vera